Nivolumab plus cabozantinib (N plus C) versus sunitinib (S) for advanced   renal cell carcinoma (aRCC): Outcomes by baseline disease   characteristics in the phase 3 CheckMate 9ER trial.

Document type:: Meeting Abstract
Author(s):: Apolo, Andrea B.; Powles, Thomas; Burotto, Mauricio; Bourlon, Maria Teresa; Hsieh, James J.; Basso, Umberto; Shah, Amishi Yogesh; Suarez, Cristina; Porta, Camillo; Barrios, Carlos H.; Gurney, Howard; Kessler, Elizabeth R.; Retz, Margitta; George, Saby; Escudier, Bernard; Zhang, Joshua; Simsek, Burcin; Scheffold, Christian; Motzer, Robert J.; Choueiri, Toni K.
Title:: Nivolumab plus cabozantinib (N plus C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.
Journal title abbreviation:: J Clin Oncol
Year:: 2021
Journal volume:: 39 Suppl S
Journal issue:: 15
Fulltext / DOI:: doi:10.1200/JCO.2021.39.15_suppl.4553
Print-ISSN:: 0732-183X
TUM Institution:: Urologische Klinik und Poliklinik
BibTeX

Occurrences: